|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||58.59 / 95.44|
The myriad names in oncology have been the hottest area for acquisitions along with gene therapy.
Market is pretty much where it has been all day, nicely positive across the board. Biotech up nearly 2% on the day. Gilead Sciences, Inc. , and Celgene Corp. , are two large caps on the move for reasons we covered in previous posts. The Bristol-Myer...
We are currently in process of restoring my access that is blocking me from seeing or commenting on the Daily Diary. We hope to have the problem resolved soon. Our apologies while getting the issue resolved. The market is off to a solid start this F...
The biotech sector isn't for the faint of heart, but these two companies issued promising news this week.
However, the RMPIA did not see as much improvement last month as some other market indices.
Experts offer their top stock ideas in oncology detection and treatment.
Acquisition deals for biotech companies at the start of 2019 are giving the sector a nice boost; here are other names that could be merger candidates.
The RMPIA rose 10.5% during the first half of the current quarter.
RMPIA soared 9.9% for the month, led by 11 double-digit gainers.
Many see the Fed as done for the year. Never assume. Read the words as they are written.
These themes are working despite the turmoil in Washington and slowing global growth.
I would add to them on any significant dips in the market.
The RMPIA is once again outpacing the S&P 500, Dow Jones Industrial Average and the Nasdaq Composite Index.
Deals that simply were unworkable four months ago because of price are now being done with alacrity.
One of pharma's biggest CEO's talks M&A action on the exchange.
The company is set to report earnings on Jan. 29, so traders have a couple of weeks to watch the action.
I would not be surprised if we see a bout of profit-taking in the near future given the sharpness of the recent rebound.
This is the kind of reversal that happens in a bull market.
Beaten-down Entercom Communications and Dynavax Technologies are off to good starts this year and should continue to improve.
The RMPIA index was up for the year, while the S&P 500, DJIA, Russell 2000 and Nasdaq all finished 2018 in the red.
It's probably no surprise that my picks for 2019 come from the biotech/biopharma space.
It's likely that investors will be closely watching the U.S.-China trade talks to see if the skies brighten longer term.
Pharma companies that have cash are looking at what has happened to this stock market and buying.
And it is happening not a moment too soon.